Aldesleukin Powder
NDC Package 68594-070-99

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is an UNFINISHED DRUG part of the official NDC directory. Unfinished drugs include products like active ingredients some of which are used in bulk for further processing or compounding. The FDA requires a list of these drugs manufactured in a U.S. commercial distribution facility.

Aldesleukin powders is aldesleukin is used to treat kidney or skin cancer. This formulation utilizes a powder delivery system. Marketed by Boehringer Ingelheim Rcv Gmbh & Co Kg, this product is identified by NDC 68594-070.

Identification & Billing

NDC Package Code
68594-070-99
Package Description
1000 mL in 1 BOTTLE
Product Code
68594-070
11-Digit Billing Format
68594007099

Clinical Specifications

Proprietary Name
Aldesleukin
Non-Proprietary Name
Aldesleukin
Substance Name
Aldesleukin
Dosage Form
Powder - An intimate mixture of dry, finely divided drugs and/or chemicals that may be intended for internal or external use.
Active Ingredient(s)
ALDESLEUKIN 1.1 mg/mL
Usage Information
Aldesleukin is used to treat kidney or skin cancer. This medication is the same as a substance that your body normally makes (interleukin-2). In the body, this drug is thought to work by affecting the body's natural defenses (immune system). This effect slows or stops cancer cell growth.

Regulatory & Marketing

Labeler Name
Boehringer Ingelheim Rcv Gmbh & Co Kg
Product Type
Drug For Further Processing
Marketing Category
DRUG FOR FURTHER PROCESSING - A drug (other than the bulk ingredient API) that is in an interim stage of manufacture, processing, preparation, or packaging, and not ready for human or animal use.
Start Marketing Date
03-30-2025
Listing Expiration
12-31-2026
Exclude Flag
N
Unfinished Product
Yes
Sample Package
N/A

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 68594-070-99 identifies a specific commercial package of 1000 ml in 1 bottle of Aldesleukin (UNFINISHED drug), drug for further processing labeled by Boehringer Ingelheim Rcv Gmbh & Co Kg. This powder is formulated for use and contains aldesleukin as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Boehringer Ingelheim Rcv Gmbh & Co Kg on March 30, 2025. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

Aldesleukin is used to treat kidney or skin cancer. This medication is the same as a substance that your body normally makes (interleukin-2). In the body, this drug is thought to work by affecting the body's natural defenses (immune system). This effect slows or stops cancer cell growth.

How is this Boehringer Ingelheim Rcv Gmbh & Co Kg product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 68594007099. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
68594-070-99
11-Digit CMS (5-4-2)
68594-0070-99

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.